Journey Medical Corporation carries a market capitalization of 195.95M, placing it among publicly traded companies globally. Its enterprise value stands at 116.37M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 195.95M |
| Enterprise Value | 116.37M |
Journey Medical Corporation currently has 27.33M shares outstanding.
| Shares Outstanding | 27.33M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
The price-to-sales ratio is 1.83, and the price-to-book ratio stands at -1.17.
| PE Ratio | N/A |
| PS Ratio | 1.83 |
| PB Ratio | -1.17 |
| P/TBV Ratio | 27.14 |
| P/FCF Ratio | -17.63 |
| P/OCF Ratio | -17.63 |
| EV / Sales | 1.80 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 18.32 |
Journey Medical Corporation maintains a current ratio of 1.72, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 82.60, indicating elevated leverage, while an interest coverage ratio of -0.52 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.72 |
| Quick Ratio | 1.38 |
| Debt / Equity | 82.60 |
| Debt / EBITDA | -13.19 |
| Interest Coverage | -0.52 |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -10.86 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.05 |
| Income Tax | 60,000.00 |
| Effective Tax Rate | N/A |
Journey Medical Corporation's stock has declined approximately -2.06327% over the past 52 weeks. The 50-day moving average sits at 6.39, while the 200-day moving average is 7.10.
| Beta (5Y) | N/A |
| 52-Week Price Change | -2.06327% |
| 50-Day Moving Average | 6.39 |
| 200-Day Moving Average | 7.10 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Journey Medical Corporation generated 64.68M in revenue and converted that into -9.59M in net income, yielding earnings per share of -0.38. EBITDA reached -1.93M, while operating income came in at -6.34M.
| Revenue | 64.68M |
| Gross Profit | 42.33M |
| Operating Income | -6.34M |
| Pretax Income | -9.53M |
| Net Income | -9.59M |
| EBITDA | -1.93M |
| EBIT | -6.34M |
| Earnings Per Share (EPS) | -0.38 |
Journey Medical Corporation holds 27.22M in cash and equivalents against 25.47M in total debt, resulting in a net debt position of -1.85M. Total book value stands at -100.68M, with working capital of 27.14M providing operational flexibility.
| Cash & Cash Equivalents | 27.22M |
| Total Debt | 25.47M |
| Net Debt | -1.85M |
| Equity (Book Value) | -100.68M |
| Book Value Per Share | -4.00 |
| Working Capital | 27.14M |
Journey Medical Corporation produced -6.70M in operating cash flow over the past twelve months.
| Operating Cash Flow | -6.70M |
| Capital Expenditures | N/A |
| Free Cash Flow | -6.70M |
| FCF Per Share | -0.27 |
Journey Medical Corporation operates with a gross margin of 65.44, reflecting its pricing power and cost economics. The operating margin of -9.80 and net profit margin of -14.82 provide insight into operational efficiency.
| Gross Margin | 65.44 |
| Operating Margin | -9.80 |
| Pretax Margin | -14.73 |
| Profit Margin | -14.82 |
| EBITDA Margin | -2.99 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -10.88 |
| FCF Yield | -5.67 |
Journey Medical Corporation posts an Altman Z-Score of 0.17, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.17 |